Article | June 29, 2018

Genomic Assays For Clinical Development: Identifying The Right Approach

Source: Q2 Solutions

By Patrick Hurban, Ph.D., Global Head, Senior Director, Translational Genomics, Q2 Solutions

Genomic Assays For Clinical Development: Identifying The Right Approach

Finding the right match for a project's requirements results in a smoother, more informed and efficient process, while the wrong assay - one that is less efficient or one that is not fit-for-purpose - leads to wasted time and money and can delay delivery of important medications to waiting patients.

Biomarker and assay selection needs change as we progress through the clinical development continuum. In very early discovery and development, the focus is on hypothesis-driven and broad-based biomarker discovery goals. As the trial progresses, biomarker-driven safety and patient stratification take center stage until finally, a targeted companion diagnostic (CDx) might be developed. Similarly, the focus for assay development changes, beginning with broad screening assays during early development and shifting to more targeted sequencing or qPCR-based approaches that more readily lend themselves to laboratory developed tests (LDTs) or in vitro diagnostics (IVDs) later in the program when regulatory requirements are critical concerns.

Download this insight brief to learn more about different genomic assays that can be used during clinical development and which ones are right for your study.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader